Novocure logo

NVCR - Novocure Share Price

$186.66 4.7  2.6%

Last Trade - 11/05/21

Large Cap
Market Cap £13.33bn
Enterprise Value £13.11bn
Revenue £373.4m
Position in Universe 621st / 6853
Unlock NVCR Revenue
Relative Strength (%)
1m +34.4%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -17.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
33.1 82.9 177 248.1 351.3 494.4 577.4 653.2 +71.7%
-65.6 +1,063
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, NovocureLtd revenues increased 32% to $134.7M. Net loss beforeextraordinary items decreased 44% to $4.1M. Revenuesreflect United States segment increase of 24% to $85.9M,Other EMEA countries segment increase from $2.7M to $8.6M.Lower net loss reflects Stock-based Compensation in SGdecrease of 5% to $8.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


NVCR Revenue Unlock NVCR Revenue

Net Income

NVCR Net Income Unlock NVCR Revenue

Normalised EPS

NVCR Normalised EPS Unlock NVCR Revenue

PE Ratio Range

NVCR PE Ratio Range Unlock NVCR Revenue

Dividend Yield Range

NVCR Dividend Yield Range Unlock NVCR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
NVCR EPS Forecasts Unlock NVCR Revenue
Profile Summary

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated February 11, 2000
Public Since October 1, 2015
No. of Shareholders: 22
No. of Employees: 1,023
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 103,413,367
Free Float (0.0%)
Eligible for
NVCR Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for NVCR
Upcoming Events for NVCR
Wednesday 9th June, 2021
Novocure Ltd Annual Shareholders Meeting
Thursday 10th June, 2021 Estimate
Novocure Ltd Annual Shareholders Meeting
Wednesday 28th July, 2021 Estimate
Q2 2021 Novocure Ltd Earnings Release
Wednesday 27th October, 2021 Estimate
Q3 2021 Novocure Ltd Earnings Release
Frequently Asked Questions for Novocure
What is the Novocure share price?

As of 11/05/21, shares in Novocure are trading at $186.66, giving the company a market capitalisation of £13.33bn. This share price information is delayed by 15 minutes.

How has the Novocure share price performed this year?

Shares in Novocure are currently trading at $186.66 and the price has moved by 0.192k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Novocure price has moved by 0.102k% over the past year.

What are the analyst and broker recommendations for Novocure?

Of the analysts with advisory recommendations for Novocure, there are there are currently 0 "buy" , 4 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Novocure is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Novocure next release its financial results?

Novocure is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Novocure dividend yield?

Novocure does not currently pay a dividend.

Does Novocure pay a dividend?

Novocure does not currently pay a dividend.

When does Novocure next pay dividends?

Novocure does not currently pay a dividend.

How do I buy Novocure shares?

To buy shares in Novocure you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Novocure?

Shares in Novocure are currently trading at $186.66, giving the company a market capitalisation of £13.33bn.

Where are Novocure shares listed? Where are Novocure shares listed?

Here are the trading details for Novocure:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: NVCR
What kind of share is Novocure?

Based on an overall assessment of its quality, value and momentum, Novocure is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Novocure share price forecast 2021?

Shares in Novocure are currently priced at $186.66. At that level they are trading at 5.33% discount to the analyst consensus target price of 0.00.

Analysts covering Novocure currently have a consensus Earnings Per Share (EPS) forecast of 0.027 for the next financial year.

How can I tell whether the Novocure share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novocure. Over the past six months, the relative strength of its shares against the market has been 24.15%. At the current price of $186.66, shares in Novocure are trading at 32.64% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Novocure PE Ratio?

The Novocure PE ratio based on its reported earnings over the past 12 months is 1.74k. The shares are currently trading at $186.66.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Novocure?

Novocure's management team is headed by:

William Doyle - CHM
Kinyip Gabriel Leung - IND
Asaf Danziger - PRE
Michael Ambrogi - VPR
Wilhelmus Groenhuysen - COO
William Vernon - LED
Todd Longsworth - GCN
David Hung - IND
Pritesh Shah - OTH
Jeryl Hilleman - IND
Ely Benaim - CEX
Ashley Cordova - CFO
Frank Leonard - OTH
Timothy Scannell - DRC
Who are the major shareholders of Novocure?

Here are the top five shareholders of Novocure based on the size of their shareholding:

Capital World Investors Investment Advisor
Percentage owned: 10.66% (11.0m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 9.29% (9.60m shares)
Baillie Gifford & Co. Investment Advisor
Percentage owned: 8.57% (8.86m shares)
Capital International Investors Investment Advisor
Percentage owned: 7.98% (8.26m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 7.97% (8.24m shares)
Similar to NVCR
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.